• Contemporary ClinicContemporary Clinic
  • OTC GuideOTC Guide
  • Pharmacy Times
  • PTCEPTCE
  • Pharmacist Moms GroupPharmacist Moms Group
News
All News
FDA Updates
Press Releases
Media
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conferences
Conference Coverage
Conference Listing
Publications
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
Clinical
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Events
Upcoming Events
Upcoming Webinars
CE
Resources
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
logo
Spotlight
Community/RetailHospitalOncologyPharmacy TechnicianStudent
Clinical Role
Community/RetailHospitalOncologyPharmacy TechnicianSpecialty PharmacyStudent
Clinical
CoronavirusBrain HealthCardiovascular HealthDermatologyDiabetesFluHeart FailureHepatitis/MASHImmunizationMigrainePneumococcalVitamins and Supplements
Supplement Spotlight
October 2023 Pharmacy Technician Edition
All News
FDA Updates
Press Releases
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conference Coverage
Conference Listing
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Upcoming Events
Upcoming Webinars
CE
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
Advertisement

CLINICAL ROLE -

Community/Retail
| Hospital
| Oncology
| Pharmacy Technician
| Student

Article

September 16, 2019

Purdue Pharma Seeks Bankruptcy Protection, Settlement of Opioid-Related Cases

Author(s):

Kristen Coppock, MA, Editor

The parties included in this agreement in principle represent some of the more than 2,600 lawsuits filed against Purdue Pharma concerning opioids, including the company’s OxyContin products.

Purdue Pharma has filed for Chapter 11 bankruptcy protection as part of a plan for settling some of the opioid-related litigation it faces in federal and state courts across the country.

These settlements have an estimated value of more than 10 billion dollars.1

The company has announced the agreement in principle for the settlement framework with 24 state attorney generals, officials from 5 United States territories, the Plaintiffs’ Executive Committee in the multidistrict litigation (MDL), and co-lead counsel in the MDL.1 The parties included in this agreement in principle represent some of the more than 2600 lawsuits filed against Purdue Pharma concerning opioids, including the company’s OxyContin products.2

The more than 2600 civil actions filed against Purdue Pharma generally allege that the company engaged in deceptive and false marketing tactics to sell its opioid products and is liable for the ongoing national opioid crisis.2

Purdue Pharma has denied claims made against the company in these lawsuits.2

In a statement, Florida’s Attorney General Ashley Moody called the agreement with Purdue Pharma “historic.”

She said that it holds the company responsible for its role in the national opioid crisis.3

“Sadly, this agreement cannot bring back those who have lost their lives to opioid abuse, but it will help Florida gain access to more life-saving resources and bolster our efforts to end this deadly epidemic. I want to assure Floridians that we will continue to aggressively pursue our state case against all remaining defendants,” Moody said. 3

According to the bankruptcy case, filed in the United States Bankruptcy Court Southern District of New York, the settlement announced would have Purdue Pharma’s shareholders transfer all the privately held company’s assets to a trust or other entity established for the benefit of claimants and for people in the United States, while relinquishing their own equity interests. All of Purdue’s ex-United States pharmaceutical companies would be sold.1,2

The new company would be governed by a new board whose members would be chosen by claimants and approved by the bankruptcy court, and it would be permanently bound to marketing restrictions on the promotion and sale of opioid products.1 In addition, the company-owning Sackler families would contribute a minimum of $3 billion to the settlement, to be paid over 7 years. 1,2

“The settlement puts the Sacklers out of the drug business permanently—not just in the United States, but around the globe. It takes every last dime that Purdue has and billions more from the Sacklers personally,” Ohio Attorney General Dave Yost said in a statement.4

In a statement released Sunday, Purdue Pharma’s Chairman Steve Miller said that the litigation resolution is expected to dedicate the company’s assets and resources for the public’s benefit.1

“This settlement framework avoids wasting hundreds of millions of dollars and year on protracted litigation, and instead will provide billions of dollars and critical resources to communities across the country trying to cope with the opioid crisis,” he said.1

Yost said years of additional litigation was the only alternative to the settlement.4

“Although there is no dollar amount that will undo the pain that so many families have faced, I’m focused on getting resources to Ohioans as quickly as possible, and this bipartisan deal makes that a reality. Ohio is in,” Miller said. 4

Purdue Pharma previously settled litigation with the State of Oklahoma with a 270 million dollar agreement that includes establishment of the National Center for Addiction Studies and Treatment at Oklahoma State University in Tulsa.5

References

  • Agreement in Principle on Landmark Opioid Litigation Settlement [news release]. Stamford, CT; September 15, 2019. https://www.purduepharma.com/news/2019/09/16/purdue-pharma-announces-agreement-in-principle-on-landmark-opioid-litigation-settlement/. Accessed September 16, 2019.
  • Debtors Informational Brief. Case 19-23649. United States Bankruptcy Court Southern District of New York. Filed September 16, 2019. Accessed September 16, 2019.
  • STATEMENT: Attorney General Moody Issues Statement on Multibillion-Dollar Agreement in Principle with Purdue Pharma [news release]. Tallahassee, FL; September 11, 2019: Florida Attorney General's website. http://www.myfloridalegal.com/newsrel.nsf/newsreleases/B4EF076EBBACB1178525847200771E99?Open&. Accessed September 16, 2019.
  • Statement From AG Yost on Purdue Pharma’s Bankruptcy Filing [news release]. Columbus, OH; September 16, 2019: Ohio Attorney General’s website. https://www.ohioattorneygeneral.gov/Media/News-Releases/September-2019/Statement-From-AG-Yost-on-Purdue-Pharma-s-Bankrupt. Accessed September 16, 2019.
  • Coppock K. Opioid Maker Agrees to Pay $270M for Addiction Treatment in Oklahoma. Pharmacy Times. https://www.pharmacytimes.com/news/opioid-mak-agrees-to-pay-270m-for-addiction-treatment-in-oklahoma. Published March 26, 2019. Accessed September 16, 2019.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Inflammation concept, inflammated human tissues 3d rendering - Image credit: picture-waterfall | stock.adobe.com
1 expert in this video
1 expert in this video
1 expert in this video
1 expert in this video
Related Content
Advertisement
Woman holds bright glowing model of digestive system. Probiotic supplements maintain digestive health, nutrient absorption, overall digestive well-being, immune support. Gastrointestinal tract - Image credit: Maryna | stock.adobe.com
July 1st 2025

Fun Fact: Cold Memories Could Warm the Body and Influence Metabolism

Kennedy Ferruggia, Assistant Editor
Pharmacy Times, Pharmacy Focus Oncology Edition
June 27th 2025

Allen's Story: The Promising Potential of Intratumoral Immunotherapy

Alexandra Gerlach, Associate Editor
Visualization of pulmonary hypertension | Image Credit: © Thirawat - stock.adobe.com
June 30th 2025

Pulmonary Hypertension Associated With Increased Risk of Progression in Patients With Myeloproliferative Neoplasms

Alexandra Gerlach, Associate Editor
Concierge Pharmacy's Role in Cardio-Kidney-Metabolic Health Care
June 17th 2025

Concierge Pharmacy's Role in Cardio-Kidney-Metabolic Health Care

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP Aislinn Antrim, Managing Editor
ASCO 2025: Using Discrete Choice Data to Support Personalized Pharmacy Counseling in ALK+ NSCLC
June 30th 2025

ASCO 2025: Using Discrete Choice Data to Support Personalized Pharmacy Counseling in ALK+ NSCLC

Christopher Danes, PhD Alana Hippensteele, Lead Editor
Streptococcus Pneumoniae Bacteria
June 30th 2025

21-Valent Pneumococcal Conjugate Vaccine Exhibits Consistent Safety and Immunogenicity Across Manufacturing Lots

Luke Halpern, Assistant Editor
Related Content
Advertisement
Woman holds bright glowing model of digestive system. Probiotic supplements maintain digestive health, nutrient absorption, overall digestive well-being, immune support. Gastrointestinal tract - Image credit: Maryna | stock.adobe.com
July 1st 2025

Fun Fact: Cold Memories Could Warm the Body and Influence Metabolism

Kennedy Ferruggia, Assistant Editor
Pharmacy Times, Pharmacy Focus Oncology Edition
June 27th 2025

Allen's Story: The Promising Potential of Intratumoral Immunotherapy

Alexandra Gerlach, Associate Editor
Visualization of pulmonary hypertension | Image Credit: © Thirawat - stock.adobe.com
June 30th 2025

Pulmonary Hypertension Associated With Increased Risk of Progression in Patients With Myeloproliferative Neoplasms

Alexandra Gerlach, Associate Editor
Concierge Pharmacy's Role in Cardio-Kidney-Metabolic Health Care
June 17th 2025

Concierge Pharmacy's Role in Cardio-Kidney-Metabolic Health Care

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP Aislinn Antrim, Managing Editor
ASCO 2025: Using Discrete Choice Data to Support Personalized Pharmacy Counseling in ALK+ NSCLC
June 30th 2025

ASCO 2025: Using Discrete Choice Data to Support Personalized Pharmacy Counseling in ALK+ NSCLC

Christopher Danes, PhD Alana Hippensteele, Lead Editor
Streptococcus Pneumoniae Bacteria
June 30th 2025

21-Valent Pneumococcal Conjugate Vaccine Exhibits Consistent Safety and Immunogenicity Across Manufacturing Lots

Luke Halpern, Assistant Editor
Consent Preferences
About Us
Clinical Forums
Advertise
Contact Us
Editorial Staff
Privacy Policy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.